Document is current
Any future updates will be listed below
-
Authors
Fandrey, Caroline I. https://orcid.org/0000-0001-6513-8877
Jentzsch, Marius
Konopka, Peter https://orcid.org/0009-0002-2373-2653
Hoch, Alexander https://orcid.org/0000-0002-4790-5507
Blumenstock, Katja
Zackria, Afraa
Maasewerd, Salie
Lovotti, Marta https://orcid.org/0000-0003-3379-2190
Lapp, Dorothee J. https://orcid.org/0000-0003-2387-8935
Gohr, Florian N.
Suwara, Piotr https://orcid.org/0000-0002-7339-8780
Świeżewski, Jędrzej https://orcid.org/0000-0001-7005-8003
Rossnagel, Lukas
Gobs, Fabienne
Cristodaro, Maia
Muhandes, Lina
Behrendt, Rayk https://orcid.org/0000-0002-1091-2877
Lam, Martin C. https://orcid.org/0000-0002-4073-7379
Walgenbach, Klaus J.
Bald, Tobias
Schmidt, Florian I. https://orcid.org/0000-0002-9979-9769
Latz, Eicke https://orcid.org/0000-0003-1488-5666
Schmid-Burgk, Jonathan L. https://orcid.org/0000-0003-0988-2487
- License Information
-
More Information
Article History
Received: 19 October 2023
Accepted: 25 November 2024
First Online: 19 December 2024
Competing interests
: C.I.F., P.K. and J.L.S.-B. are inventors on a patent application related to nuclear in situ sequencing and pooled optical screening. J.L.S.-B. is a co-founder and shareholder of LAMPseq Diagnostics and ions.bio. E.L. and F.I.S. are co-founders and consultants of Odyssey Therapeutics. E.L. is a co-founder of Beren Therapeutics, Metaimmune Therapeutics and IFM Therapeutics. The other authors declare no competing interests.
